Nutriband Inc.

Equities

NTRB

US67092M2089

Medical Equipment, Supplies & Distribution

Market Closed - OTC Markets Other stock markets 01:30:00 08/06/2024 am IST			5-day change	1st Jan Change
5.2 ^USD	-2.62%		-4.59%	+124.14%

31/05	Nutriband Inc. Reports Earnings Results for the First Quarter Ended April 30, 2024	CI
16/05	Nutriband Inc. Appoints Sergei Glinka to Its Board of Directors	CI

Nutriband Inc. Appoints Sean Gallagher as Company President and to the Board of Directors

February 13, 2018 at 07:00 pm IST

Nutriband Inc. announced the appointment of Sean Gallagher as company president and to the Board of Directors. Gallaher's notable business ventures include co-founding and serving as CEO of Clyde Real Estate, Pharmaceutical Directorships, and co-founding, Smarthomes. Gallagher has also served as an investor on the TV show Dragon's Den, Ireland and UK's version of Shark Tank.

Latest news about Nutriband Inc.

Nutriband Inc. Reports Earnings Results for the First Quarter Ended April 30, 2024	31/05	CI
Nutriband Inc. Appoints Sergei Glinka to Its Board of Directors	16/05	CI
Tranche Update on Nutriband Inc.'s Equity Buyback Plan announced on December 30, 2021.	01/05	CI
Tranche Update on Nutriband Inc.'s Equity Buyback Plan announced on December 30, 2021.	01/05	CI
Tranche Update on Nutriband Inc.'s Equity Buyback Plan announced on December 30, 2021.	01/05	CI
Nutriband Inc. Reports Earnings Results for the Full Year Ended January 31, 2024	01/05	CI
Nutriband Inc. Closes $8.4 Million Private Placement for Commercial Development of Aversa(R) Fentanyl Transdermal Patch Through FDA Submission	24/04	CI
Nutriband Inc. announced that it expects to receive $8.4 million in funding	23/04	CI
Nutriband Inc. Receives First Order from Fit for Life Group	01/04	CI
Nutriband Inc. Provides Clinical and Regulatory Path Overview for Lead Product - AVERSA(R) Fentanyl Transdermal Patch	27/03	CI
Nutriband Inc. Announces Data Supporting Need for Safer Abuse-Deterrent Transdermal Patches Presented At 2024 American Academy of Pain Medicine Annual Meeting	25/03	CI
Nutriband Inc. Announces Data on the Incidence of Transdermal Patch Abuse and Accidental Pediatric Exposure Will Be Presented At the 2024 American Academy of Pain Medicine Annual Meeting	04/03	CI
Nutriband Signs Agreement With Kindeva Drug Delivery for Aversa Fentanyl	05/01	MT
Nutriband Inc. Signs Commercial Development and Clinical Supply Agreement With Kindeva Drug Delivery for Aversa(TM) Fentanyl, an Abuse Deterrent Fentanyl Patch	05/01	CI
Nutriband Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2023	13/12	CI
Nutriband Introduces Kinesiology Tape With Heating, Cooling Features	28/11	MT
Nutriband Inc. Expands its AI Kinesiology Tape Portfolio with the Launch of AI Tape Heating and Cooling	28/11	CI
Nutriband Signs Supplier Deal With KT Tape	08/11	MT
Nutriband Inc. Signs Supplier Agreement with KT Tape	08/11	CI
Top Premarket Decliners	07/11	MT
Sector Update: Health Care Stocks Softer Late Afternoon	12/23/12	MT
Sector Update: Health Care	12/23/12	MT
Nutriband Says Buprenorphine Product Has Potential to Reach Up to $130 Million in Annual US Sales	12/23/12	MT
Nutriband Secures US Patent for Abuse Deterrent Transdermal Products	20/23/20	MT
Nutriband Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2023	11/23/11	CI

Chart Nutriband Inc.

Duration

Period

More charts

Company Profile

Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

Sector

Medical Equipment, Supplies & Distribution

Calendar

30/08/2024 - Q2 2025 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
NUTRIBAND INC.	+124.14%	57.39M
ABBOTT LABORATORIES	-2.26%	187B
MEDTRONIC PLC	+2.05%	110B
BECTON, DICKINSON AND COMPANY	-1.31%	69.54B
CENCORA, INC.	+14.65%	46.37B
DEXCOM, INC.	-6.69%	46.05B
HOYA CORPORATION	+7.97%	42.54B
METTLER-TOLEDO INTERNATIONAL, INC.	+18.60%	30.72B
TERUMO CORPORATION	+16.92%	25.62B
ZIMMER BIOMET HOLDINGS, INC.	-6.87%	23.32B

Other Medical Equipment, Supplies & Distribution

Nutriband Inc.

Equities

NTRB

US67092M2089

Medical Equipment, Supplies & Distribution

Nutriband Inc. Appoints Sean Gallagher as Company President and to the Board of Directors

Latest news about Nutriband Inc.

Chart Nutriband Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Medical Equipment, Supplies & Distribution